BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 22439935)

  • 1. Treatment-emergent mutations in NAEβ confer resistance to the NEDD8-activating enzyme inhibitor MLN4924.
    Milhollen MA; Thomas MP; Narayanan U; Traore T; Riceberg J; Amidon BS; Bence NF; Bolen JB; Brownell J; Dick LR; Loke HK; McDonald AA; Ma J; Manfredi MG; Sells TB; Sintchak MD; Yang X; Xu Q; Koenig EM; Gavin JM; Smith PG
    Cancer Cell; 2012 Mar; 21(3):388-401. PubMed ID: 22439935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations in UBA3 confer resistance to the NEDD8-activating enzyme inhibitor MLN4924 in human leukemic cells.
    Xu GW; Toth JI; da Silva SR; Paiva SL; Lukkarila JL; Hurren R; Maclean N; Sukhai MA; Bhattacharjee RN; Goard CA; Medeiros B; Gunning PT; Dhe-Paganon S; Petroski MD; Schimmer AD
    PLoS One; 2014; 9(4):e93530. PubMed ID: 24691136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantifiable analysis of cellular pathway inhibition of a Nedd8-activating enzyme inhibitor, MLN4924, using AlphaScreen.
    Yan ZH; Burkhardt A; Loke HK; Chen J; Xu Q; Brauer P; Ma J; Lin Y; Garcia K; Dick LR; Bembenek ME
    Anal Biochem; 2013 Aug; 439(2):109-15. PubMed ID: 23624319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ.
    Brownell JE; Sintchak MD; Gavin JM; Liao H; Bruzzese FJ; Bump NJ; Soucy TA; Milhollen MA; Yang X; Burkhardt AL; Ma J; Loke HK; Lingaraj T; Wu D; Hamman KB; Spelman JJ; Cullis CA; Langston SP; Vyskocil S; Sells TB; Mallender WD; Visiers I; Li P; Claiborne CF; Rolfe M; Bolen JB; Dick LR
    Mol Cell; 2010 Jan; 37(1):102-11. PubMed ID: 20129059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A gatekeeper residue for NEDD8-activating enzyme inhibition by MLN4924.
    Toth JI; Yang L; Dahl R; Petroski MD
    Cell Rep; 2012 Apr; 1(4):309-16. PubMed ID: 22832224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absolute quantification of E1, ubiquitin-like proteins and Nedd8-MLN4924 adduct by mass spectrometry.
    Yang X; Brownell JE; Xu Q; Zhu F; Ma J; Loke HK; Rollins N; Soucy TA; Minissale JJ; Thomas MP; Mallender WD; Dick LR; Li P; Liao H
    Cell Biochem Biophys; 2013 Sep; 67(1):139-47. PubMed ID: 23754621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neddylation Inactivation Facilitates FOXO3a Nuclear Export to Suppress Estrogen Receptor Transcription and Improve Fulvestrant Sensitivity.
    Jia X; Li C; Li L; Liu X; Zhou L; Zhang W; Ni S; Lu Y; Chen L; Jeong LS; Yu J; Zhang Y; Zhang J; He S; Hu X; Sun H; Yu K; Liu G; Zhao H; Zhang Y; Jia L; Shao ZM
    Clin Cancer Res; 2019 Jun; 25(12):3658-3672. PubMed ID: 30833270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular dynamics investigation on the poor sensitivity of A171T mutant NEDD8-activating enzyme (NAE) for MLN4924.
    Verma S; Singh A; Mishra A
    J Biomol Struct Dyn; 2014; 32(7):1064-73. PubMed ID: 23782099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The NEDD8-activating enzyme inhibition with MLN4924 sensitizes human cancer cells of different origins to apoptosis and necroptosis.
    El-Mesery M; Anany MA; Hazem SH; Shaker ME
    Arch Biochem Biophys; 2020 Sep; 691():108513. PubMed ID: 32721435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nedd8-activating enzyme inhibitor MLN4924 (Pevonedistat), inhibits miR-1303 to suppress human breast cancer cell proliferation via targeting p27
    Chen Y; Du M; Yusuying S; Liu W; Tan Y; Xie P
    Exp Cell Res; 2020 Jul; 392(2):112038. PubMed ID: 32360865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The NEDD8-activating enzyme inhibitor MLN4924 induces G2 arrest and apoptosis in T-cell acute lymphoblastic leukemia.
    Han K; Wang Q; Cao H; Qiu G; Cao J; Li X; Wang J; Shen B; Zhang J
    Oncotarget; 2016 Apr; 7(17):23812-24. PubMed ID: 26993774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nedd8-Activating Enzyme Is a Druggable Host Dependency Factor of Human and Mouse Cytomegalovirus.
    Flores-Martínez YA; Le-Trilling VTK; Trilling M
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program.
    Smith MA; Maris JM; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Reynolds CP; Kang MH; Morton CL; Wu J; Smith PG; Yu J; Houghton PJ
    Pediatr Blood Cancer; 2012 Aug; 59(2):246-53. PubMed ID: 22012946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disrupting protein NEDDylation with MLN4924 is a novel strategy to target cisplatin resistance in ovarian cancer.
    Nawrocki ST; Kelly KR; Smith PG; Espitia CM; Possemato A; Beausoleil SA; Milhollen M; Blakemore S; Thomas M; Berger A; Carew JS
    Clin Cancer Res; 2013 Jul; 19(13):3577-90. PubMed ID: 23633453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor.
    Wei D; Li H; Yu J; Sebolt JT; Zhao L; Lawrence TS; Smith PG; Morgan MA; Sun Y
    Cancer Res; 2012 Jan; 72(1):282-93. PubMed ID: 22072567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Nedd8-activating enzyme inhibitor MLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth.
    Luo Z; Yu G; Lee HW; Li L; Wang L; Yang D; Pan Y; Ding C; Qian J; Wu L; Chu Y; Yi J; Wang X; Sun Y; Jeong LS; Liu J; Jia L
    Cancer Res; 2012 Jul; 72(13):3360-71. PubMed ID: 22562464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AKT inhibitor MK-2206 sensitizes breast cancer cells to MLN4924, a first-in-class NEDD8-activating enzyme (NAE) inhibitor.
    Chen X; Cui D; Bi Y; Shu J; Xiong X; Zhao Y
    Cell Cycle; 2018; 17(16):2069-2079. PubMed ID: 30198810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synaptic structure and function are altered by the neddylation inhibitor MLN4924.
    Scudder SL; Patrick GN
    Mol Cell Neurosci; 2015 Mar; 65():52-7. PubMed ID: 25701678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer.
    Soucy TA; Smith PG; Milhollen MA; Berger AJ; Gavin JM; Adhikari S; Brownell JE; Burke KE; Cardin DP; Critchley S; Cullis CA; Doucette A; Garnsey JJ; Gaulin JL; Gershman RE; Lublinsky AR; McDonald A; Mizutani H; Narayanan U; Olhava EJ; Peluso S; Rezaei M; Sintchak MD; Talreja T; Thomas MP; Traore T; Vyskocil S; Weatherhead GS; Yu J; Zhang J; Dick LR; Claiborne CF; Rolfe M; Bolen JB; Langston SP
    Nature; 2009 Apr; 458(7239):732-6. PubMed ID: 19360080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative proteomic analysis of cellular protein modulation upon inhibition of the NEDD8-activating enzyme by MLN4924.
    Liao H; Liu XJ; Blank JL; Bouck DC; Bernard H; Garcia K; Lightcap ES
    Mol Cell Proteomics; 2011 Nov; 10(11):M111.009183. PubMed ID: 21873567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.